Shares of Johnson & Johnson (JNJ) slid nearly 3.5% in morning trading Tuesday after the pharma giant's first-quarter earnings results were met with mixed reactions from investors. As the sell-off continues, investors focused on large-cap pharma companies may want to move their money into stronger options this earnings season.
Johnson & Johnson (JNJ) reported mixed first quarter results, with earnings beating expectations while sales missing the same.
Key highlights this week included pipeline updates from companies like Geron (GERN) and OncoMed.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Verizon, Visa, General Dynamics and Abbott
United Therapeutics Corporation (UTHR) shares plunged around 9% on Monday after the company announced that regulatory issues will delay the planned U.S. launch of RemoSynch - an implantable pump for delivering Remodulin
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
This week's highlights include rumors regarding Sanofi (SNY) acquiring Flexion, accelerated FDA approval for a Pfizer/Merck KGaA drug and drug pricing.
Zacks Industry Outlook Highlights: GlaxoSmithKline, Celgene and Exelixis
Zacks Industry Outlook Highlights: Johnson & Johnson, Pfizer, Glaxo, Amgen’s and Lilly
United Therapeutics Corporation (UTHR) reported adjusted earnings of $2.64 per share for fourth-quarter 2016, which missed the Zacks Consensus Estimate of $3.62 by 27.1%.
Key highlights this week include a court ruling in the Copaxone patent infringement lawsuit and earnings results from companies like Pfizer (PFE).
Major highlights this week were earnings results from companies like Celgene (CELG) and pipeline updates.